Does the media prefer VALN or SLS?

In the previous week, SELLAS Life Sciences Group had 9 more articles in the media than Valneva. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 1 mentions for Valneva. SELLAS Life Sciences Group's average media sentiment score of 0.21 beat Valneva's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, VALN or PHVS?

Valneva has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.82 -$130.33M -$2.11 N/A Pharvaris N/A N/A -$198.79M -$3.05 N/A

Is VALN or PHVS more profitable?

Pharvaris has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Pharvaris' return on equity of -61.40% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -110.33% -153.20% -39.50% Pharvaris N/A -61.40% -56.00%

Does the media refer more to VALN or PHVS?

In the previous week, Pharvaris had 6 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Pharvaris and 1 mentions for Valneva. Pharvaris' average media sentiment score of 0.63 beat Valneva's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PVLA or VALN?

In the previous week, Palvella Therapeutics had 8 more articles in the media than Valneva. MarketBeat recorded 9 mentions for Palvella Therapeutics and 1 mentions for Valneva. Palvella Therapeutics' average media sentiment score of 0.69 beat Valneva's score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BCRX or VALN?

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Valneva. MarketBeat recorded 3 mentions for BioCryst Pharmaceuticals and 1 mentions for Valneva. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat Valneva's score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, BHVN or VALN?

Valneva has higher revenue and earnings than Biohaven. Valneva is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Valneva $197.56M 2.82 -$130.33M -$2.11 N/A

Is BHVN or VALN more profitable?

Biohaven has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Valneva's return on equity of -153.20% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Valneva -110.33% -153.20% -39.50%

Does the media prefer BHVN or VALN?

In the previous week, Biohaven had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Biohaven and 1 mentions for Valneva. Valneva's average media sentiment score of 0.00 beat Biohaven's score of -0.40 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Valneva (VALN) Competitors

$5.74 -0.16 (-2.71%)

Closing price 04:00 PM Eastern

Extended Trading

$5.78 +0.04 (+0.70%)

As of 04:10 PM Eastern

Compare

VALN vs. SLS, PHVS, PVLA, BCRX, and BHVN

Should you buy Valneva stock or one of its competitors? Valneva's main competitors and comparable companies include SELLAS Life Sciences Group (SLS), Pharvaris (PHVS), Palvella Therapeutics (PVLA), BioCryst Pharmaceuticals (BCRX), and Biohaven (BHVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Valneva compare to SELLAS Life Sciences Group?

Valneva (NASDAQ:VALN) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

11.4% of Valneva shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Valneva. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.82	-$130.33M	-$2.11	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A

Valneva has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.56, indicating that its stock price is 156% more volatile than the broader market.

SELLAS Life Sciences Group has a net margin of 0.00% compared to Valneva's net margin of -110.33%. SELLAS Life Sciences Group's return on equity of -35.91% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%

Valneva presently has a consensus price target of $9.30, suggesting a potential upside of 58.43%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential downside of 15.54%. Given Valneva's higher possible upside, equities analysts plainly believe Valneva is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SELLAS Life Sciences Group had 9 more articles in the media than Valneva. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 1 mentions for Valneva. SELLAS Life Sciences Group's average media sentiment score of 0.21 beat Valneva's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	0 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SELLAS Life Sciences Group beats Valneva on 11 of the 15 factors compared between the two stocks.

How does Valneva compare to Pharvaris?

Valneva (NASDAQ:VALN) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Valneva presently has a consensus target price of $9.30, suggesting a potential upside of 58.43%. Pharvaris has a consensus target price of $59.87, suggesting a potential upside of 92.29%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts clearly believe Pharvaris is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Valneva has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.82	-$130.33M	-$2.11	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

In the previous week, Pharvaris had 6 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Pharvaris and 1 mentions for Valneva. Pharvaris' average media sentiment score of 0.63 beat Valneva's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Pharvaris' return on equity of -61.40% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Pharvaris	N/A	-61.40%	-56.00%

Valneva has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.46, meaning that its stock price is 346% less volatile than the broader market.

11.4% of Valneva shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Valneva beats Pharvaris on 8 of the 15 factors compared between the two stocks.

How does Valneva compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Palvella Therapeutics has higher earnings, but lower revenue than Valneva. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	44.53	-$41.72M	-$4.83	N/A
Valneva	$197.56M	2.82	-$130.33M	-$2.11	N/A

Palvella Therapeutics currently has a consensus price target of $209.14, suggesting a potential upside of 58.09%. Valneva has a consensus price target of $9.30, suggesting a potential upside of 58.43%. Given Valneva's higher possible upside, analysts clearly believe Valneva is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Palvella Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Palvella Therapeutics' return on equity of -47.84% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Valneva	-110.33%	-153.20%	-39.50%

Palvella Therapeutics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the broader market. Comparatively, Valneva has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

In the previous week, Palvella Therapeutics had 8 more articles in the media than Valneva. MarketBeat recorded 9 mentions for Palvella Therapeutics and 1 mentions for Valneva. Palvella Therapeutics' average media sentiment score of 0.69 beat Valneva's score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Palvella Therapeutics beats Valneva on 12 of the 17 factors compared between the two stocks.

How does Valneva compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Valneva (NASDAQ:VALN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Valneva's net margin of -110.33%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Valneva	-110.33%	-153.20%	-39.50%

BioCryst Pharmaceuticals presently has a consensus target price of $20.50, indicating a potential upside of 155.77%. Valneva has a consensus target price of $9.30, indicating a potential upside of 58.43%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

BioCryst Pharmaceuticals has higher revenue and earnings than Valneva. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.34	$263.86M	-$1.50	N/A
Valneva	$197.56M	2.82	-$130.33M	-$2.11	N/A

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Valneva. MarketBeat recorded 3 mentions for BioCryst Pharmaceuticals and 1 mentions for Valneva. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat Valneva's score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Valneva has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Summary

BioCryst Pharmaceuticals beats Valneva on 12 of the 16 factors compared between the two stocks.

How does Valneva compare to Biohaven?

Biohaven (NYSE:BHVN) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biohaven presently has a consensus price target of $18.69, indicating a potential upside of 47.15%. Valneva has a consensus price target of $9.30, indicating a potential upside of 58.43%. Given Valneva's higher possible upside, analysts clearly believe Valneva is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Biohaven has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Valneva's return on equity of -153.20% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Valneva	-110.33%	-153.20%	-39.50%

In the previous week, Biohaven had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Biohaven and 1 mentions for Valneva. Valneva's average media sentiment score of 0.00 beat Biohaven's score of -0.40 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valneva has higher revenue and earnings than Biohaven. Valneva is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Valneva	$197.56M	2.82	-$130.33M	-$2.11	N/A

Biohaven has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Valneva has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Summary

Valneva beats Biohaven on 9 of the 16 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VALN vs. The Competition

Export

Metric	Valneva	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$559.83M	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	-2.72	7.65	214.49	21.54
Price / Sales	2.76	1,292.25	607.75	91.81
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	4.13	16.63	10.92	6.30
Net Income	-$130.33M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-6.51%	-3.05%	-2.11%	-1.67%
1 Month Performance	-19.38%	-10.75%	-6.34%	-3.94%
1 Year Performance	-49.96%	21.11%	8.81%	2.77%

Valneva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VALN Valneva	1.6771 of 5 stars	$5.74 -2.7%	$9.30 +62.0%	-49.0%	$559.83M	$197.56M	N/A	674	Positive News Gap Down
SLS SELLAS Life Sciences Group	0.3954 of 5 stars	$12.02 +5.7%	$10.00 -16.8%	+570.4%	$2.43B	N/A	N/A	13
PHVS Pharvaris	4.2515 of 5 stars	$35.20 -2.3%	$59.87 +70.1%	+28.9%	$2.30B	N/A	N/A	148
PVLA Palvella Therapeutics	2.6229 of 5 stars	$158.13 +3.1%	$209.14 +32.3%	+109.9%	$2.28B	$42.81M	N/A	29
BCRX BioCryst Pharmaceuticals	2.3515 of 5 stars	$8.78 +0.2%	$20.40 +132.3%	+10.2%	$2.24B	$940.61M	N/A	435	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VALN) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valneva (VALN) Competitors

VALN vs. SLS, PHVS, PVLA, BCRX, and BHVN

How does Valneva compare to SELLAS Life Sciences Group?

Summary

How does Valneva compare to Pharvaris?

Summary

How does Valneva compare to Palvella Therapeutics?

Summary

How does Valneva compare to BioCryst Pharmaceuticals?

Summary

How does Valneva compare to Biohaven?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valneva (VALN) Competitors

VALN vs. SLS, PHVS, PVLA, BCRX, and BHVN

How does Valneva compare to SELLAS Life Sciences Group?

Do insiders & institutionals believe in VALN or SLS?

Which has preferable earnings & valuation, VALN or SLS?

Which has more volatility and risk, VALN or SLS?

Is VALN or SLS more profitable?

Do analysts prefer VALN or SLS?

Does the media prefer VALN or SLS?

Summary

How does Valneva compare to Pharvaris?

Do analysts rate VALN or PHVS?

Which has preferable valuation & earnings, VALN or PHVS?

Does the media refer more to VALN or PHVS?

Is VALN or PHVS more profitable?

Which has more risk and volatility, VALN or PHVS?

Do insiders & institutionals hold more shares of VALN or PHVS?

Summary

How does Valneva compare to Palvella Therapeutics?

Do institutionals and insiders hold more shares of PVLA or VALN?

Which has preferable valuation & earnings, PVLA or VALN?

Do analysts recommend PVLA or VALN?

Is PVLA or VALN more profitable?

Which has more volatility and risk, PVLA or VALN?

Does the media prefer PVLA or VALN?

Summary

How does Valneva compare to BioCryst Pharmaceuticals?

Do insiders & institutionals believe in BCRX or VALN?

Is BCRX or VALN more profitable?

Do analysts rate BCRX or VALN?

Which has preferable valuation & earnings, BCRX or VALN?

Does the media prefer BCRX or VALN?

Which has more volatility and risk, BCRX or VALN?

Summary

How does Valneva compare to Biohaven?

Do insiders & institutionals believe in BHVN or VALN?

Do analysts recommend BHVN or VALN?

Is BHVN or VALN more profitable?

Does the media prefer BHVN or VALN?

Which has better earnings and valuation, BHVN or VALN?

Which has more volatility and risk, BHVN or VALN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools